Corey J. Langer, M.D.

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-138
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-5121
Fax: 215-615-5122
Lab: CP 215-806-6152
B.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Maturing role of immunotherapy in advanced NSCLC.
Role of targeted agents in oncogene-driven NSCLC
New strategies in SCLC
Unique combined modality strategies integrating radiation and systemic treatment in LA-NSCLC and limited stage SCLC
Underserved populations, including older patients and those with compromised performance status.
Novel therapeutic venues in thoracic and head and neck cancer

Description of Clinical Expertise

Thoracic Medical Oncology with focus on NSCLC, SCLC, and Mesothelioma

Selected Publications

Wang X, Katz S, Miura J, Karakousis G, Roshkovan L, Walker S, McNulty S, Ciunci C, Cengel K, Langer CJ, Marmarelis ME.: A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma. PLoS One. 17(9): e0275187, September 2022.

Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR.: Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clin Res Rep. 3(9): 100385, July 2022 Notes: doi: 10.1016/j.jtocrr.2022.100385.

Ciunci CA, Reibel JB, Evans TL, Mick R, Bauml JM, Aggarwal C, Marmarelis ME, Singh AP, D'Avella C, Cohen RB, Langer CJ: Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed. Clin Lung Cancer. 23(4), June 2022.

Marmarelis ME, Yang YX, Hwang WT, Mamtani R, Singh A, Ciunci C, Aggarwal C, Cohen RB, Langer CJ.: Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. Clin Lung Cancer 23(4): e301-e309, June 2022.

Thompson JC, Aggarwal C, Wong J, Nimgaonkar V, Hwang WT, Andronov M, Dibardino DM, Hutchinson CT, Ma KC, Lanfranco A, Moon E, Haas AR, Singh AP, Ciunci CA, Marmarelis M, D'Avella C, Cohen JV, Bauml JM, Cohen RB, Langer CJ, Vachani A, Carpenter EL: Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study. JTO Clin Res Rep. 3(4), March 2022.

Powell SF, Rodríguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, Rodríguez-Cid J, Kowalski DM, Cheng Y, Kurata T, Awad MM, Lin J, Zhao B, Pietanza MC, Piperdi B, Garassino MC.: Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. doi: 10.1016/j.jtho.2021.06.020. Epub 2021 Jul 12. (eds.). 16(11): 1883-1892, November 2021.

Nimgaonkar V, Aggarwal C, Berman AT, Gabriel P, Shulman LN, Kucharczuk J, Roy M, Bauml JM, Singh AP, Cohen RB, Langer CJ, Marmarelis ME.: Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic. BMC Cancer. doi: 10.1186/s12885-021-08819-z. (eds.). 21(1): 1094, October 2021.

Kish JA, Zhang Q, Langer CJ, Nguyen-Tân PF, Rosenthal DI, Weber RS, List MA, Wong SJ, Garden AS, Hu K, Trotti AM, Bonner JA, Jones CU, Yom SS, Thorstad W, Schultz CJ, Ridge JA, Shenouda G, Harris J, Le QT.: The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. J Geriatr Oncol. doi: 10.1016/j.jgo.2021.03.011. Epub 2021 Apr 2. (eds.). 12(6): 937-944, July 2021.

Sun L, Hsu M, Cohen RB, Langer CJ, Mamtani R, Aggarwal C.: Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JAMA Oncol. doi: 10.1001/jamaoncol.2021.0546. (eds.). 7(6): 937-939, June 2021.

Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Özgüroğlu M, Daniel D, Vicente D, Murakami S, Langer C, Senan S, Spigel D, Rydén A, Zhang Y, O'Brien C, Dennis PA, Antonia SJ.: Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol. doi: 10.2217/fon-2020-1102. Epub 2021 Feb 15. (eds.). 17(10): 1165-1184, April 2021.

back to top
Last updated: 12/08/2022
The Trustees of the University of Pennsylvania